Video

Neoadjuvant IO Therapy Trials in Resectable CSCC and Cemiplimab Data Updates

A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Thach-Giao Truong, MD, medical director, Melanoma Program, Cleveland Clinic